Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK1 | P23458 | 18/20 | 0.68 |
| ▸ | JAK2 | O60674 | 15/20 | 0.68 |
| ▸ | JAK3 | P52333 | 1/20 | 0.58 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26078106 | 1.00 | JAK1 (0.68) | JAK1JAK2JAK3KCNH2 | |
| SCHEMBL24474791 | 1.00 | JAK1 (0.68) | JAK1JAK2JAK3KCNH2 | |
| SCHEMBL30712651 | 1.00 | JAK1 (0.68) | JAK1JAK2JAK3KCNH2 | |
| SCHEMBL24475193 | 1.00 | JAK1 (0.68) | JAK1JAK2JAK3KCNH2 | |
| SCHEMBL30712648 | 0.93 | JAK1 (0.67) | JAK1JAK2JAK3KCNH2 | |
| SCHEMBL24474787 | 0.93 | JAK1 (0.67) | JAK1JAK2JAK3KCNH2 | |
| SCHEMBL24474793 | 0.93 | JAK1 (0.67) | JAK1JAK2JAK3KCNH2 | |
| SCHEMBL30712652 | 0.92 | JAK1 (0.67) | JAK1JAK2JAK3KCNH2 | |
| SCHEMBL24474789 | 0.92 | JAK1 (0.67) | JAK1JAK2JAK3KCNH2 | |
| SCHEMBL29170662 | 0.92 | JAK1 (0.67) | JAK1JAK2JAK3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12630539-B2 | Amide compound, pharmaceutical composition and use thereof | ARTIVILA (SHENZHEN) INNOVATION CENTER, LTD. (CN) | 2026-05-19 | — | — | US | disclosed |
| EP-4253375-B1 | AMIDE COMPOUND, PHARMACEUTICAL COMPOSITION AND USE THEREOF | ARTIVILA SHENZHEN INNOVATION CENTER LTD (CN) | 2026-01-07 | — | — | EP | disclosed |
| US-20230416237-A1 | AMIDE COMPOUND, PHARMACEUTICAL COMPOSITION AND USE THEREOF | ARTIVILA (SHENZHEN) INNOVATION CENTER, LTD. (CN) | 2023-12-28 | — | — | US | disclosed |
| EP-4253375-A1 | AMIDE COMPOUND, PHARMACEUTICAL COMPOSITION AND USE THEREOF | Artivila (ShenZhen) Innovation Center, Ltd. (CN) | 2023-10-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12630539-B2 | Amide compound, pharmaceutical composition and use thereof | JAK2, JAK1, JAK3 | JAK1 2/4885JAK2 1/4885JAK3 3/4885 |
| US-20230416237-A1 | AMIDE COMPOUND, PHARMACEUTICAL COMPOSITION AND USE THEREOF | JAK1, JAK2, JAK3 | JAK1 1/4885JAK2 2/4885JAK3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.